Weighing the risks and benefits of GLP-1 drugs for kids struggling with obesity

With childhood and teen obesity rates hitting alarming highs, the FDA's approval of GLP-1 drugs for weight loss in kids aged 12 and older marks a significant shift in how we tackle this growing health crisis. Dr. Rachel Pessah-Pollack delves into the potential benefits these medications could offer, such as aiding in weight management, while also weighing the risks, including possible side effects and long-term impacts. This move is crucial as it could provide a new avenue for addressing obesity, but it also raises important questions about the appropriateness and safety of such treatments for younger populations.